Gefitinib response of erlotinib-refractory lung cancer involving meninges - Role of EGFR mutation

Nicholas W. Choong, Sascha Dietrich, Tanguy Lim Seiwert, Maria S. Tretiakova, Vidya Nallasura, Gareth C. Davies, Stanley Lipkowitz, Aliya N. Husain, Ravi Salgia, Patrick C. Ma

Research output: Contribution to journalArticle

Abstract

Background: A 70-year-old Japanese -American woman who had never smoked was diagnosed with stage IV non-small-cell lung cancer with rib metastases. She had previously been well and she had no family history of malignancy. While receiving treatment with erlotinib, an epidermal growth factor receptor small-molecule inhibitor, she progressed and developed new brain metastases. She failed further chemotherapy treatments and subsequently developed extensive symptomatic leptomeningeal carcinomatosis associated with diplopia, hemiparesis, weight loss, and incontinence. Investigations: Chest X-ray, head and chest CT scan, R2 lymph-node biopsy, histopathology, immunohistochemistry, MRI of head and spine, lumbar puncture, laser microdissection and EGFR genomic DNA sequencing of the R2 lymph node and cerebrospinal fluid tumor cells. Diagnosis: Erlotinib-refractory stage IV lung adenocarcinoma and end-stage symptomatic leptomeningeal metastases with a novel double L858R + E884K somatic mutation of the EGFR. Management: Carboplatin, paclitaxel and erlotinib, whole-brain radiotherapy, temozolomide with and without irinotecan, and gefitinib.

Original languageEnglish (US)
Pages (from-to)50-57
Number of pages8
JournalNature Clinical Practice Oncology
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2006
Externally publishedYes

Fingerprint

Meninges
Lung Neoplasms
irinotecan
temozolomide
Neoplasm Metastasis
Mutation
Thorax
Lymph Nodes
Head
Meningeal Carcinomatosis
Microdissection
Spinal Puncture
Diplopia
Asian Americans
Carboplatin
Brain
Paresis
Ribs
Paclitaxel
DNA Sequence Analysis

Keywords

  • Epidermal growth factor receptor
  • Leptomeningeal carcinomatosis
  • Lung cancer
  • Mutation
  • Small-molecule inhibitor

ASJC Scopus subject areas

  • Oncology

Cite this

Gefitinib response of erlotinib-refractory lung cancer involving meninges - Role of EGFR mutation. / Choong, Nicholas W.; Dietrich, Sascha; Lim Seiwert, Tanguy; Tretiakova, Maria S.; Nallasura, Vidya; Davies, Gareth C.; Lipkowitz, Stanley; Husain, Aliya N.; Salgia, Ravi; Ma, Patrick C.

In: Nature Clinical Practice Oncology, Vol. 3, No. 1, 01.01.2006, p. 50-57.

Research output: Contribution to journalArticle

Choong, NW, Dietrich, S, Lim Seiwert, T, Tretiakova, MS, Nallasura, V, Davies, GC, Lipkowitz, S, Husain, AN, Salgia, R & Ma, PC 2006, 'Gefitinib response of erlotinib-refractory lung cancer involving meninges - Role of EGFR mutation', Nature Clinical Practice Oncology, vol. 3, no. 1, pp. 50-57. https://doi.org/10.1038/ncponc0400
Choong, Nicholas W. ; Dietrich, Sascha ; Lim Seiwert, Tanguy ; Tretiakova, Maria S. ; Nallasura, Vidya ; Davies, Gareth C. ; Lipkowitz, Stanley ; Husain, Aliya N. ; Salgia, Ravi ; Ma, Patrick C. / Gefitinib response of erlotinib-refractory lung cancer involving meninges - Role of EGFR mutation. In: Nature Clinical Practice Oncology. 2006 ; Vol. 3, No. 1. pp. 50-57.
@article{6293055119514045a8e751364ee77b72,
title = "Gefitinib response of erlotinib-refractory lung cancer involving meninges - Role of EGFR mutation",
abstract = "Background: A 70-year-old Japanese -American woman who had never smoked was diagnosed with stage IV non-small-cell lung cancer with rib metastases. She had previously been well and she had no family history of malignancy. While receiving treatment with erlotinib, an epidermal growth factor receptor small-molecule inhibitor, she progressed and developed new brain metastases. She failed further chemotherapy treatments and subsequently developed extensive symptomatic leptomeningeal carcinomatosis associated with diplopia, hemiparesis, weight loss, and incontinence. Investigations: Chest X-ray, head and chest CT scan, R2 lymph-node biopsy, histopathology, immunohistochemistry, MRI of head and spine, lumbar puncture, laser microdissection and EGFR genomic DNA sequencing of the R2 lymph node and cerebrospinal fluid tumor cells. Diagnosis: Erlotinib-refractory stage IV lung adenocarcinoma and end-stage symptomatic leptomeningeal metastases with a novel double L858R + E884K somatic mutation of the EGFR. Management: Carboplatin, paclitaxel and erlotinib, whole-brain radiotherapy, temozolomide with and without irinotecan, and gefitinib.",
keywords = "Epidermal growth factor receptor, Leptomeningeal carcinomatosis, Lung cancer, Mutation, Small-molecule inhibitor",
author = "Choong, {Nicholas W.} and Sascha Dietrich and {Lim Seiwert}, Tanguy and Tretiakova, {Maria S.} and Vidya Nallasura and Davies, {Gareth C.} and Stanley Lipkowitz and Husain, {Aliya N.} and Ravi Salgia and Ma, {Patrick C.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1038/ncponc0400",
language = "English (US)",
volume = "3",
pages = "50--57",
journal = "Nature Clinical Practice Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Gefitinib response of erlotinib-refractory lung cancer involving meninges - Role of EGFR mutation

AU - Choong, Nicholas W.

AU - Dietrich, Sascha

AU - Lim Seiwert, Tanguy

AU - Tretiakova, Maria S.

AU - Nallasura, Vidya

AU - Davies, Gareth C.

AU - Lipkowitz, Stanley

AU - Husain, Aliya N.

AU - Salgia, Ravi

AU - Ma, Patrick C.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Background: A 70-year-old Japanese -American woman who had never smoked was diagnosed with stage IV non-small-cell lung cancer with rib metastases. She had previously been well and she had no family history of malignancy. While receiving treatment with erlotinib, an epidermal growth factor receptor small-molecule inhibitor, she progressed and developed new brain metastases. She failed further chemotherapy treatments and subsequently developed extensive symptomatic leptomeningeal carcinomatosis associated with diplopia, hemiparesis, weight loss, and incontinence. Investigations: Chest X-ray, head and chest CT scan, R2 lymph-node biopsy, histopathology, immunohistochemistry, MRI of head and spine, lumbar puncture, laser microdissection and EGFR genomic DNA sequencing of the R2 lymph node and cerebrospinal fluid tumor cells. Diagnosis: Erlotinib-refractory stage IV lung adenocarcinoma and end-stage symptomatic leptomeningeal metastases with a novel double L858R + E884K somatic mutation of the EGFR. Management: Carboplatin, paclitaxel and erlotinib, whole-brain radiotherapy, temozolomide with and without irinotecan, and gefitinib.

AB - Background: A 70-year-old Japanese -American woman who had never smoked was diagnosed with stage IV non-small-cell lung cancer with rib metastases. She had previously been well and she had no family history of malignancy. While receiving treatment with erlotinib, an epidermal growth factor receptor small-molecule inhibitor, she progressed and developed new brain metastases. She failed further chemotherapy treatments and subsequently developed extensive symptomatic leptomeningeal carcinomatosis associated with diplopia, hemiparesis, weight loss, and incontinence. Investigations: Chest X-ray, head and chest CT scan, R2 lymph-node biopsy, histopathology, immunohistochemistry, MRI of head and spine, lumbar puncture, laser microdissection and EGFR genomic DNA sequencing of the R2 lymph node and cerebrospinal fluid tumor cells. Diagnosis: Erlotinib-refractory stage IV lung adenocarcinoma and end-stage symptomatic leptomeningeal metastases with a novel double L858R + E884K somatic mutation of the EGFR. Management: Carboplatin, paclitaxel and erlotinib, whole-brain radiotherapy, temozolomide with and without irinotecan, and gefitinib.

KW - Epidermal growth factor receptor

KW - Leptomeningeal carcinomatosis

KW - Lung cancer

KW - Mutation

KW - Small-molecule inhibitor

UR - http://www.scopus.com/inward/record.url?scp=30944434263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30944434263&partnerID=8YFLogxK

U2 - 10.1038/ncponc0400

DO - 10.1038/ncponc0400

M3 - Article

C2 - 16407879

AN - SCOPUS:30944434263

VL - 3

SP - 50

EP - 57

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

SN - 1759-4774

IS - 1

ER -